Biricodar: A New Drug for Neuroblastoma Treatment
Author Information
Author(s): Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton C R, Pritchard-Jones K
Primary Institution: The Institute of Cancer Research/Royal Marsden NHS Trust
Hypothesis
The study investigates the role of multidrug resistance (MDR) in neuroblastoma and the effectiveness of Biricodar as a chemosensitizer.
Conclusion
The study found that Biricodar can effectively sensitize neuroblastoma cells to chemotherapy drugs, particularly in MDR1-positive lines.
Supporting Evidence
- The study characterized six neuroblastoma cell lines for drug resistance markers.
- Biricodar was found to consistently sensitize MDR1-positive neuroblastoma cells to vincristine.
- The study confirmed the role of MDR1 and MRP in chemoresistance in neuroblastoma.
Takeaway
Researchers tested a new drug called Biricodar to see if it helps make cancer treatments work better for kids with a type of cancer called neuroblastoma.
Methodology
The study characterized neuroblastoma cell lines for drug resistance markers and evaluated the effects of various chemosensitizers using cytotoxicity assays.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website